

## Special Issue

# Current Molecular Research on Skin Diseases

### Message from the Guest Editors

COVID-19 revolutionized daily clinical practice. In particular, several strategies were adopted to avoid the spreading of the infection as well as the epidemiology, and the management of several dermatological conditions completely changed, for example, psoriasis, atopic dermatitis, hidradenitis suppurativa, and skin cancers. Several skin manifestations were related to COVID-19 itself, as well as the safety of many dermatological treatments, such as biological drugs, was questioned during the pandemic. Among the measures adopted to avoid the propagation of the infection, telemedicine was crucial to allowing therapeutic assistance without increasing the risk of the infection. Similarly, the introduction of the COVID-19 vaccination had the greatest impact on overcoming the pandemic. This Special Issue is now open for submissions, welcoming papers that bring together the most relevant scientific research investigating how COVID-19 impacted the management of skin diseases, focusing on epidemiology and treatment, as well as the role of teledermatology in the pandemic period and of the dermatologist during the vaccination campaign.

### Guest Editors

Dr. Luca Potestio

Prof. Dr. Gabriella Fabbrocini

Dr. Matteo Megna

Dr. Angelo Ruggiero

### Deadline for manuscript submissions

closed (30 June 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/159100](https://mdpi.com/si/159100)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).